Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients
Chachar et al.,
Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,
International Journal of Sciences, 9:31-35, doi:10.18483/ijSci.2378
Small RCT with 25 ivermectin and 25 control patients, not finding a significant difference in recovery at day 7.
risk of no recovery at day 7, 10.0% lower, RR 0.90, p = 0.50, treatment 9 of 25 (36.0%), control 10 of 25 (40.0%), NNT 25, primary outcome.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Chachar et al., 30 Sep 2020, Randomized Controlled Trial, India, peer-reviewed, 6 authors, dosage 36mg, 12mg stat, 12mg after 12 hours, 12mg after 24 hours.
Abstract: Effectiveness of Ivermectin in
SARS-CoV-2/COVID-19 Patients
Aijaz Zeeshan Khan Chachar, Khurshid Ahmed Khan,
Mohsin Asif, Khushbakht, Arous Khaqan, Rabia Basri
Abstract: Background:The first case of Infection with severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) were diagnosed in Wuhan, China in 2019. In the first half of 2020 this disease has already converted into a
global pandemic. Objectives: To assess the efficacy of Ivermectin in mild cases of COVID-19 patients on the basis
of predefined assessment criteria. Study Settings: Fatima Memorial Hospital, Lahore Study Design: Open label
randomized control trial. Duration of Study: From 1st May, 2020 to 30th June, 2020.Patients & Methods: Sample size
and technique: Sample size was 50 patients; 25 patients were kept in control group and 25 patients were kept in
experimental group. Results: There were total 50 patients, divided into two groups case and control group.The mean
age of the participants was 40.60 ± 17 and out of those 31 (62%) were male and 19 (38%) were females. Cough was
observed more in case group (p= 0.049). Fever, myalgias and dyspnea were the commonest symptoms in both the
groups (p= 1.000). Diarrhea and vomiting were more common in control group (p=0.0001, p= 0.042 respectively).
On follow up at day 7, patients were stratified as asymptomatic and symptomatic. Amongst the case group, out of 25
patients, 16(64%) patients were asymptomatic and rest of the 9(36%) patients was asymptomatic. In control group,
out of 25 patients, 15(60%) patients were asymptomatic and rest of the 10(40%) patients was asymptomatic. p-value
(0.500). Statistically there was no significant difference between case group who were given ivermectin along with
symptomatic treatment and control group who were only given symptomatic treatment without ivermectin, being
asymptomatic on day 7 at follow up. p-value (0.500)
Keywords: Corona Virus, Covid-19, SARS-COv-2, Antiviral, Ivermectin, Pandemic
The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is a single-stranded ribonucleic acid
(RNA) virus that causes a severe acute respiratory
syndrome. The virus was originally called SARSCoV-2 named officially by World Health
Organization as COVID-19 and a global health
emergency. The first known case of infection was
recorded in early December 2019 and subsequently
spread to various continents, including Europe and
the United States2, 3Generally, 75 percent of patients
recover without any notable complication however
25 percent can experience associated complications
leading to intensive care unit transfer and even
mortality.4
and anti-cancer properties and considered as a
wonder drug. It is highly effective against many
microorganisms including some viruses.5 Many
studies revealed its antiviral effects on RNA viruses
such as Zika, dengue, yellow fever, West Nile,
Hendra, Newcastle, Venezuelan equine encephalitis,
chikungunya, Semliki Forest, Sindbis, Avian
influenza A, Porcine Reproductive and Respiratory
Syndrome, Human immunodeficiency virus(HIV)
type 1, and severe acute respiratory syndrome
coronavirus SARS-CoV-2. Fon other hand there are
few studies showing antiviral effects of ivermectin
against DNA viruses such as Equine herpes type 1,
BK polyomavirus, pseudorabies, porcine circovirus
2, and bovine herpesvirus 1.5 Ivermectin plays a vital
role in several biological mechanisms, therefore it
could emerge as a potential candidate in the treatment
of a wide range of viruses including..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit